217
Participants
Start Date
December 31, 2006
Primary Completion Date
December 31, 2010
Study Completion Date
December 31, 2010
Abatacept
Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants \< 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants \> 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.
Local Institution, Shimotsuke-Shi
Local Institution, Fukui-shi
Local Institution, Fukui-shi
Local Institution, Nagoya
Local Institution, Nagoya
Local Institution, Goshogawara-Shi
Local Institution, Chiba
Local Institution, Sendai
Local Institution, Fukui-shi
Local Institution, Fukuoka
Local Institution, Fukuoka
Local Institution, Kitakyushu-Shi
Local Institution, Higashi-Hiroshima-Shi
Local Institution, Sapporo
Local Institution, Sapporo
Local Institution, Sapporo
Local Institution, Kanzaki-Gun
Local Institution, Kato-Gun
Local Institution, Hitachi-Shi
Local Institution, Tsukuba
Local Institution, Sagamihara-Shi
Local Institution, Sendai
Local Institution, Sendai
Local Institution, Nagano
Local Institution, Tsukubo-Gun
Local Institution, Kawachinagano-Shi
Local Institution, Ureshino-Shi
Local Institution, Iruma-Gun
Local Institution, Kawagoe-Shi
Local Institution, Kitamoto-Shi
Local Institution, Hamamatsu
Local Institution, Kawachigun
Local Institution, Arakawa-Ku
Local Institution, Bunkyo-Ku
Local Institution, Bunkyo-Ku
Local Institution, Setagaya-Ku
Local Institution, Shinjuku-Ku
Local Institution, Takaoka-Shi
Local Institution, Chiba
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY